CAD 0.05
(0.0%)
Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
---|---|---|---|---|---|---|
Revenue | - | - | - | - | - | - |
Cost of Revenue | 144.11 Thousand | 46.87 Thousand | 59.5 Thousand | 97.45 Thousand | 103.88 Thousand | 101.42 Thousand |
Gross Profit | -144.11 Thousand | -46.87 Thousand | -59.5 Thousand | -97.45 Thousand | -103.88 Thousand | -101.42 Thousand |
Operating Expenses | 11.77 Million | 12.65 Million | 6.35 Million | 6.27 Million | 8.89 Million | 9.48 Million |
Selling, General and Administrative Expenses | 6.32 Million | 11.38 Million | 6.6 Million | 5.17 Million | 5.58 Million | 6.16 Million |
Research and Development Expenses | - | - | - | - | - | - |
Other Expenses | 5.45 Million | 1.26 Million | -250.7 Thousand | 1.09 Million | 3.3 Million | 3.32 Million |
Cost and Expenses | 11.77 Million | 12.69 Million | 6.41 Million | 6.37 Million | 8.99 Million | 9.58 Million |
Operating Income | -11.77 Million | -14.06 Million | -6.43 Million | -5.79 Million | -8.99 Million | -9.16 Million |
Interest Expense | 231.00 | 1344.00 | 2342.00 | 3932.00 | 6574.00 | - |
Income Tax Expense | - | 1.37 Million | 2342.00 | 3932.00 | 6574.00 | 1.52 Million |
Earnings before Tax | -10.71 Million | -13.34 Million | -6.2 Million | -5.48 Million | -7.98 Million | -8.06 Million |
Net Income | -10.71 Million | -14.72 Million | -6.2 Million | -5.49 Million | -7.99 Million | -8.06 Million |
Earnings Per Share Basic | -0.02 | -0.03 | -0.01 | -0.01 | -0.02 | -0.02 |
Earnings Per Share Diluted | -0.02 | -0.03 | -0.01 | -0.01 | -0.02 | -0.02 |
Weighted Average Shares Outstanding | 455.05 Million | 455.05 Million | 455.05 Million | 450.89 Million | 444.1 Million | 453.95 Million |
Weighted Average Shares Outstanding (Diluted) | 455.05 Million | 455.05 Million | 455.05 Million | 450.89 Million | 444.1 Million | 453.95 Million |
Gross Margin | - | - | - | - | - | - |
EBIT Margin | - | - | - | - | - | - |
Profit Margin | - | - | - | - | - | - |
EBITDA | -10.57 Million | -13.3 Million | -6.14 Million | -5.38 Million | -7.87 Million | -9.48 Million |
Earnings Before Tax Margin | - | - | - | - | - | - |
Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 |
---|---|---|---|---|---|---|
Revenue | - | - | - | - | - | - |
Cost of Revenue | 9823.00 | 10.23 Thousand | 144.11 Thousand | 114.41 Thousand | 3409.00 | 15.18 Thousand |
Gross Profit | -9823.00 | -10.23 Thousand | -144.11 Thousand | -114.41 Thousand | -3409.00 | -15.18 Thousand |
Operating Expenses | 2.76 Million | 1.51 Million | 6.32 Million | 1.6 Million | 1.66 Million | 1.7 Million |
Selling, General and Administrative Expenses | 2.76 Million | 1.51 Million | - | 1.6 Million | 1.27 Million | 1.26 Million |
Research and Development Expenses | - | - | - | - | - | - |
Other Expenses | 221.1 Thousand | - | - | - | - | - |
Cost and Expenses | 2.77 Million | 1.52 Million | 6.46 Million | 1.71 Million | 1.66 Million | 1.72 Million |
Operating Income | -2.77 Million | -1.52 Million | -6.46 Million | -1.71 Million | -1.75 Million | -1.79 Million |
Interest Expense | - | - | 231.00 | 7.00 | - | 195.00 |
Income Tax Expense | -3.00 | -2.00 | 3.00 | 70.59 Thousand | -181.53 Thousand | 195.00 |
Earnings before Tax | -2.71 Million | -1.37 Million | -10.71 Million | -6.59 Million | -1.48 Million | -1.53 Million |
Net Income | -2.71 Million | -1.37 Million | -10.71 Million | -6.59 Million | -1.48 Million | -1.53 Million |
Earnings Per Share Basic | -0.01 | -0.00 | - | -0.01 | -0.00 | -0.00 |
Earnings Per Share Diluted | -0.01 | -0.00 | - | -0.01 | -0.00 | -0.00 |
Weighted Average Shares Outstanding | 455.05 Million | 455.05 Million | 455.05 Million | 455.05 Million | 455.05 Million | 455.05 Million |
Weighted Average Shares Outstanding (Diluted) | 455.05 Million | 455.05 Million | 455.05 Million | 455.05 Million | 455.05 Million | 455.05 Million |
Gross Margin | - | - | - | - | - | - |
EBIT Margin | - | - | - | - | - | - |
Profit Margin | - | - | - | - | - | - |
EBITDA | -2.76 Million | -1.51 Million | - | -1.6 Million | -1.57 Million | -1.45 Million |
Earnings Before Tax Margin | - | - | - | - | - | - |
VSTTILLERS
TRIP
DRUG
ELAB
300175
6412